University of North Carolina at Chapel Hill

China Medical University

National Science Council

Medical and Pharmaceutical Industry Technology and Development Center

China Medical University Hospital

Tairx, Inc.

National Science Council of Taiwan

Tian-Shung Wu

Kuo-Hsiung Lee

Sheng-Chu Kuo

Che-Ming Teng

Li-Jiau Huang

Jai-Sing Yang

Tzong-Der Way

Shiow-Lin Pan

Li-Chen Chou

Jing-Gung Chung

Chung-Ming Sun

Chih-Shiang Chang

Shih-Ming Huang

Ching-Che Huang

Chien-Ting Chen

Jang-Chang Lee

Feng-Nien Ko

Kenneth F Bastow

Sheu-Meei Yu

Min-Tsang Hsieh

Ling-Chu Chang

Hsin-Yi Hung

Xihong Wang

Yang-Chang Wu

Arnold Brossi

Woei-Cherng Shyu

Chen-Huan Lin

Mo-Chi Cheng

Chi-Hung Huang

Hui-Yi Lin

Xiaoming Yang

Chung Y Hsu

Leping Li

Hui K Wang

Linyi Wei

Meng-Tung Tsai

Keduo Qian

Ying-Qian Liu

Masuo Goto

Huei-Wen Chen

Chih-Ya Wang

Yung-Yi Cheng

Chin-Yu Liu

Zhi-Jun Zhang

Mei-Juan Wang

Liu Yang

Yong-Long Zhao

Huei-Wan Chen

Hui-yi Lin

Min-tsang Hsieh

The present invention is related to novel 20-sulfonylamidine derivatives of camptothecin (1), method of synthesizing the same, and use thereof as an antitumor agent, for examples an antitumor agent for treating nasopharyngeal, lung, breast or prostate cancer.

[object Object]

The present invention provides a series of derivatives of stilbenoid which are useful as new inhibitory agents against head and neck squamous cell carcinoma (HNSCC) and hepatoma.

Stilbenoid compound as inhibitor for squamous carcinoma and hepatoma and uses thereof

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Naform) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

2-phenyl-4-quinolones as anticancer agents

2-selenophene-4-quinolones as anticancer agents

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Naform) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents

A compound of Formula I is disclosed as follows: 

Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and &#x39b;/, &#x39b;/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents

Compounds of Formula I are described: preferably subject to the proviso that either (a) Rand Rtogether form &#x2014;O&#x2014;CH(R)&#x2014;O&#x2014;, or (b) Rand Rtogether form &#x2014;O&#x2014;CH(R)&#x2014;O&#x2014;, wherein Ris H, halo, or loweralkyl. Pharmaceutical salts, formulations, and methods of using the same in the treatment of cancer are also described. 

Tylophorine analogs as antitumor agents

Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.

Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents

A polygalatenoside useful as an antidepressant agent having the formula is disclosed: wherein R, R' and R&#x2033; independently are H or R, provided that R, R&#x2032; and R&#x2033; are not all H, wherein Ris wherein Ris hydrogen, C1-C6 alkyl, C1-C6 alkoxy or halogen; or a pharmaceutically acceptable salt thereof. Preferably, Ris H.

Polygalatenosides and use thereof as an antidepressant agent

Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmeutical formulations thereof.

A method of treating a patient suffering a disease associated withorby applying topically an anti-fungal pharmaceutical composition which is prepared from, includes the following steps: preparing a crude liquid from rhizomes of ginger by extraction with an organic solvent or supercritical CO, or by distillation with steam; introducing the crude liquid to a reverse phase chromatography column, and eluting the column with water, a first eluent and a second eluent having a polarity weaker than that of the first eluent but stronger than that of chloroform, so that a first eluate resulting from elution of the first eluent and a second eluate resulting from elution of the second eluent are obtained; removing the first eluent and the second eluent from the first eluate and the second eluate by evaporation, respectively, so that a first concentrated eluate and a second concentrated eluate are obtained as the potent extract.

Anti-fungal pharmaceutical compositions comprising an active ingredient prepared from Zingiber officinale

A method of preparing an extract from,, which is potent in anti-inflammation and anti-platelet aggregation, includes the following steps: a) preparing a crude liquid from rhizomes of ginger by extraction with an organic solvent or by distillation with steam; b) introducing the crude liquid to a reverse phase chromatography column, and eluting the column with water, a first eluent and a second eluent having a polarity weaker than that of the first eluent but stronger than that of chloroform, so that a first eluate resulting from elution of the first eluent and a second eluate resulting from elution of the second eluent are obtained; c) removing the first eluent from the first eluate by evaporation, so that a first concentrated eluate is obtained and is able to used as the potent extract; and d) removing the second eluent from the second eluate by evaporation, so that a second concentrated eluate is obtained and is able to used as the potent extract.

Method of preparing an extract potent in anti-inflammation and anti-platelet aggregation from Zingiber officinale and pharmaceutical compositions containing said extract

A pharmaceutical composition which possesses vasorelaxing effect of aortic contraction, relaxing effect of tracheal contraction, and antioxidative properties, is disclosed. It contains a pharmaceutical acceptable vehicle and an effective amount of any compound selected from those compounds represented by the following formula: ##STR1## where R.sub.1 represents H, C.sub.1-8 alkyl, or --OCOR, R.sub.2 represents OH, or COO.sup.--, and R represents H, or C.sub.1-8 alkyl.

Thromboxane A2 Receptor antagonism and antioxidant action of

The present invention discloses the method of isolation and purification of the bioactive constituents cinnamophilin from Cinnamomum philippinense (Merr.), the same as Machilus acuminatissima (Hayata). Pharmacological evaluation showed that these compounds possess the activity to inhibit platelet aggregation and to produce relaxing effects of aortic vascular constriction.

Thromboxane A.sub.2 receptor antagonism and antioxidant action of

Growing community of inventors

Tainan, Taiwan

Tian-Shung Wu